Price Alert

PTC Therapeutics Inc. (PTCT)

NASDAQ: PTCT · Real-Time Price · USD

57.26

-0.75 (-1.29%)

At close: Sep 05, 2025, 3:59 PM

57.26

0.00%

After-hours: Sep 05, 2025, 04:42 PM EDT

PTC Therapeutics Statistics

Share Statistics

PTC Therapeutics has 79.44M shares outstanding. The number of shares has increased by 3.03% in one year.

Shares Outstanding	79.44M
Shares Change (YoY)	3.03%
Shares Change (QoQ)	0.49%
Owned by Institutions (%)	99.99%
Shares Floating	76.03M
Failed to Deliver (FTD) Shares	33
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 6.5M, so 8.18% of the outstanding shares have been sold short.

Short Interest	6.5M
Short % of Shares Out	8.18%
Short % of Float	9.4%
Short Ratio (days to cover)	5.06

Valuation Ratios

The PE ratio is -9.55 and the forward PE ratio is -20.5. PTC Therapeutics's PEG ratio is 0.22.

PE Ratio	-9.55
Forward PE	-20.5
PS Ratio	4.3
Forward PS	5.3
PB Ratio	-3.16
P/FCF Ratio	-30.38
PEG Ratio	0.22

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for PTC Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.35, with a Debt / Equity ratio of -2.25.

Current Ratio	2.35
Quick Ratio	2.31
Debt / Equity	-2.25
Debt / EBITDA	-20.51
Debt / FCF	-21.64
Interest Coverage	-1.81

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$859.19K
Profits Per Employee	$-386.9K
Employee Count	939
Asset Turnover	0.47
Inventory Turnover	2.47

Taxes

Income Tax	176K
Effective Tax Rate	-0.05%

Stock Price Statistics

The stock price has increased by 81.55% in the last 52 weeks. The beta is 0.53, so PTC Therapeutics's price volatility has been higher than the market average.

Beta	0.53
52-Week Price Change	81.55%
50-Day Moving Average	49.27
200-Day Moving Average	48.36
Relative Strength Index (RSI)	69.7
Average Volume (20 Days)	1,195,580

Income Statement

In the last 12 months, PTC Therapeutics had revenue of 806.78M and earned -363.3M in profits. Earnings per share was -4.73.

Revenue	806.78M
Gross Profit	749.38M
Operating Income	-302.57M
Net Income	-363.3M
EBITDA	-120.46M
EBIT	-196.13M
Earnings Per Share (EPS)	-4.73

Full Income Statement

Balance Sheet

The company has 779.71M in cash and 2.47B in debt, giving a net cash position of -1.69B.

Cash & Cash Equivalents	779.71M
Total Debt	2.47B
Net Cash	-1.69B
Retained Earnings	-3.65B
Total Assets	2.63B
Working Capital	1.65B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -107.69M and capital expenditures -6.5M, giving a free cash flow of -114.19M.

Operating Cash Flow	-107.69M
Capital Expenditures	-6.5M
Free Cash Flow	-114.19M
FCF Per Share	-1.49

Full Cash Flow Statement

Margins

Gross margin is 92.89%, with operating and profit margins of -37.5% and -45.03%.

Gross Margin	92.89%
Operating Margin	-37.5%
Pretax Margin	-45.01%
Profit Margin	-45.03%
EBITDA Margin	-14.93%
EBIT Margin	-37.5%
FCF Margin	-14.15%

Dividends & Yields

PTCT does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for PTCT is $66.5, which is 16.1% higher than the current price. The consensus rating is "Buy".

Price Target	$66.5
Price Target Difference	16.1%
Analyst Consensus	Buy
Analyst Count	13

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	1.67
Piotroski F-Score	7